Monrovia, CA -- (SBWire) -- 03/15/2011 -- Susan Schneider, Ph.D., Director, Discovery Medicine, GSK Ophthalmology will present on Systemic Administration of an Anti-Amyloid Beta Monoclonal Antibody Interferes with the Ocular Pathology of a Mouse Model of Age-Related Macular Degeneration at GTC’s 3rd Ocular Diseases & Drug Discovery Conference on May 26-27, 2011 in Boston, MA.

Susan Schneider will present her topic on Age-Related Macular Degeneration, discussing how Neovascular AMD has effective treatments, but no effective therapies currently available for dry AMD. Data now support involvement of the alternative complement pathway in AMD development. A transgenic CFH-gene deficient mouse model shows hallmarks of early AMD.

Cfh-/- mice were treated systemically in both prophylactic and therapeutic regimes with a GSK anti-amyloid beta monoclonal antibody to determine the effect on the cfh-/- retinal phenotype.

GTC’s Ocular Diseases conference will also have featured presenter Barbara Wirostko from Altheos. This event will bring together leaders from Neurotech, ORA, the John A. Moran Eye Center, Santen, Allergan, and more. Updates on age-related macular degeneration, recent drug developments and mechanisms, rho kinase inhibitors, and the future of ocular disease therapeutics will be addressed and discussed.

GTCbio’s 3rd Ocular Disease & Drug Discovery Conference will provide cutting edge information and a chance to exchange ideas from leading experts in the field. Don’t miss this opportunity to register for GTC’s Ocular Diseases conference at https://www.gtcbio.com/index.php?option=com_register&cn=3rd%20Ocular%20Diseases%20&cid=23